Other Team Members

This guide will explans how to choose a screening tool for Perinatal Mood and Anxiety Disorders (PMADs), provides recommendations and resources on how to administer the tools, recommends additional screening tools, presents an algorithm and response protocol, and briefly touches on establishing outside resources and referrals.

This toolkit is tailored specifically to the unique needs of multidisciplinary substance use disorder (SUD) providers and programs serving perinatal individuals. It is meant to be a quick reference resource about mental health and SUD specific to perinatal individuals.

This toolkit provides tools to both providers and patients for the assessment and management of perinatal mood and anxiety disorders, as well as substance use disorders (SUD).

This web page outlines policies on substance use during pregnancy, categorizing how these policies differ from state to state.

This Guide to meant to help health care teams recognize, rethink and remediate the stigma and bias of words commonly used in caring for people with the chronic disease of substance use disorder:

This resource offers background information and tips for providers on how to use person-first language and on which terms to avoid using to reduce stigma and negative bias when discussing addiction or substance use disorder with pregnant women and mothers.

This implementation guide serves to provide other medical clinics seeking to integrate maternal mental health care into obstetric and/or pediatric settings with best practices for doing so.

The Drug Free Moms and Babies (DFMB) Project is a comprehensive and integrative medical and behavioral health program for pregnant and postpartum women. The project supports healthy baby outcomes by providing prevention, early intervention, addiction treatment, and recovery support services.

MaineMOM aims to improve care for pregnant and postpartum people with opioid use disorder and their infants by integrating maternal and substance use treatment services.

This document summarizes a discussion from a workshop where experts examined the evidence for candidate endpoints and study design strategies for clinical trials of stimulant use disorder treatments.